Parainfluenza virus infection Market: Epidemiology, Therapies, Companies, DelveInsight | Ansun Biopharma, AlloVir

Parainfluenza virus infection therapies, such as DAS181, ALVR106, and others, are expected to boost the Parainfluenza virus infection Market in the upcoming years.

DelveInsight has launched a new report on "Parainfluenza virus infection - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Parainfluenza virus infection, historical and forecasted epidemiology as well as the Parainfluenza virus infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Parainfluenza virus infection market report @ https://www.delveinsight.com/report-store/parainfluenza-virus-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Parainfluenza virus infection Market Report:

According to DelveInsight's analysts, the number of Parainfluenza Virus Infection cases in the 7MM was estimated to be around 2,709,923 in 2023, with an expected increase in cases over the forecast period (2024-2034).
In June 2024, scientists at Vanderbilt University Medical Center identified antibodies that block PIV infection, particularly human PIV type 3 (hPIV3), which can cause severe respiratory illness in children and immunocompromised individuals. These findings could pave the way for antibody-based therapies or vaccines in the future.
The highest number of Parainfluenza Virus Infection cases in 2023 was recorded in the US, followed by Japan, Spain, and Germany.
In the 7MM, the Parainfluenza Virus Infection Drugs Market primarily consisted of standard treatments, which generated approximately USD 259 million in 2023.
The overall Parainfluenza Virus Infection Treatment Market is expected to grow during the forecast period, driven by the rising number of PIV infection cases.
According to DelveInsight's projections, the total number of Parainfluenza Virus Infection cases in the United States was 1,456,399 in 2023, with an expected increase during the forecast period.
In the EU4 countries and the UK, DelveInsight estimates that there were 991,115 Parainfluenza Virus Infection cases in 2023. Among the EU4 nations, Spain had the highest proportion of cases, while the UK reported the lowest number.
The Parainfluenza Virus Infection Therapeutics Market is expected to see positive growth in the coming years.
In 2023, the total market size for Parainfluenza Virus Infection in the 7MM was approximately USD 259 million, with projections indicating significant growth at a strong CAGR by 2034.
Among the 7MM, the US held the largest share of the Parainfluenza Virus Infection market in 2023, accounting for 68% of the total, followed by EU4 and the UK, which are also expected to grow during the forecast period (2024-2034).
In 2023, EU4 and the UK represented nearly 23% of the total Parainfluenza Virus Infection drugs market across the 7MM.
Japan held the second-largest market share for Parainfluenza Virus Infection drugs across all 7MM and is expected to see further growth by 2034.
The number of Parainfluenza Virus Infection cases in Japan was approximately 262,409 in 2023, and this number is expected to rise by 2034.
Key Parainfluenza virus infection companies such as Ansun Biopharma, AlloVir, and others are evaluating new drugs for Parainfluenza virus infection to improve the treatment landscape.
Promising Parainfluenza virus infection therapies include DAS181, ALVR106, and others.

Parainfluenza virus infection Overview

Parainfluenza virus (PIV) infection is a respiratory illness caused by one of four types of parainfluenza viruses: PIV-1, PIV-2, PIV-3, and PIV-4. These viruses are part of the Paramyxoviridae family and primarily target the respiratory system, resulting in various infections like the common cold, croup, bronchiolitis, and pneumonia. PIV infection is typically spread through respiratory droplets released when an infected person coughs, sneezes, or talks. It can also spread indirectly by touching contaminated surfaces.

The symptoms of PIV infection vary based on the type and severity of the illness, but common signs include those of the common cold, such as a runny nose, cough, sore throat, and fever. In more severe cases, symptoms may progress to include breathing difficulties, wheezing, and chest pain.

Parainfluenza virus infection Market Outlook

Currently, the main approach to treating Parainfluenza Virus Infection involves supportive care, with the exception of croup, where corticosteroids have been found to be helpful. New treatments, such as DAS181, show potential for managing severe cases in immunocompromised patients and are still under development. Despite ongoing efforts, effective treatment options for Parainfluenza Virus Infection are limited, and there are no approved medications to address this significant gap in care. Specifically, there is no FDA-approved cure or antiviral treatment for Parainfluenza Virus Infection.

Most cases of Parainfluenza Virus Infection resolve on their own without the need for specific medical treatment. However, supportive measures, such as sufficient rest, hydration, and over-the-counter medications to alleviate symptoms, may be recommended. In more severe cases or for individuals with weakened immune systems, antiviral drugs or hospitalization may be required. Ribavirin is sometimes used off-label for treating PIV infections due to its in vitro activity, but its effectiveness remains uncertain, as there is insufficient data from randomized trials.

Discover how the Parainfluenza virus infection market is rising in the coming years @ https://www.delveinsight.com/sample-request/parainfluenza-virus-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Parainfluenza virus infection Emerging Drugs
DAS181: Ansun Biopharma
ALVR106: AlloVir

Scope of the Parainfluenza virus infection Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Parainfluenza virus infection Companies: Ansun Biopharma, AlloVir, and others
Key Parainfluenza virus infection Therapies: DAS181, ALVR106, and others
Parainfluenza virus infection Therapeutic Assessment: Parainfluenza virus infection current marketed and Parainfluenza virus infection emerging therapies
Parainfluenza virus infection Market Dynamics: Parainfluenza virus infection market drivers and Parainfluenza virus infection market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Parainfluenza virus infection Unmet Needs, KOL's views, Analyst's views, Parainfluenza virus infection Market Access and Reimbursement

To know what's more in our Parainfluenza virus infection report, visit https://www.delveinsight.com/report-store/parainfluenza-virus-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Parainfluenza virus infection Market Report:
Parainfluenza virus infection market report covers a descriptive overview and comprehensive insight of the Parainfluenza virus infection Epidemiology and Parainfluenza virus infection market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Parainfluenza virus infection market report provides insights into the current and emerging therapies.
The Parainfluenza virus infection market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Parainfluenza virus infection market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Parainfluenza virus infection market.

Got queries? Click here to know more about the Parainfluenza virus infection market Landscape https://www.delveinsight.com/sample-request/parainfluenza-virus-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Parainfluenza virus infection Patient Share (%) Overview at a Glance
5. Parainfluenza virus infection Market Overview at a Glance
6. Parainfluenza virus infection Disease Background and Overview
7. Parainfluenza virus infection Epidemiology and Patient Population
8. Country-Specific Patient Population of Parainfluenza virus infection
9. Parainfluenza virus infection Current Treatment and Medical Practices
10. Unmet Needs
11. Parainfluenza virus infection Emerging Therapies
12. Parainfluenza virus infection Market Outlook
13. Country-Wise Parainfluenza virus infection Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Parainfluenza virus infection Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Parainfluenza virus infection Market Outlook 2034 https://www.delveinsight.com/report-store/parainfluenza-virus-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Parainfluenza virus infection Pipeline Insights, DelveInsight

"Parainfluenza virus infection Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Parainfluenza virus infection market. A detailed picture of the Parainfluenza virus infection pipeline landscape is provided, which includes the disease overview and Parainfluenza virus infection treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.